September 2020 Briefing - HIV & AIDS
Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Hospital Admissions Not Related to COVID-19 Fell in Early 2020
WEDNESDAY, Sept. 30, 2020 (HealthDay News) -- Non-COVID-19 hospital admissions decreased considerably with the onset of COVID-19, with declines generally similar across patient demographic subgroups from February to April 2020, according to a report published online Sept. 24 in Health Affairs.
Thousands of Donated Corneas From Gay, Bisexual Men Rejected
TUESDAY, Sept. 29, 2020 (HealthDay News) -- An estimated 1,558 to 3,217 corneal donations were disqualified in 2018 because of federal regulations prohibiting corneal donation by men who have sex with men (MSM), according to a study published online Sept. 24 in JAMA Ophthalmology.
Private Health Plans Pay Hospitals 247 Percent of Medicare
MONDAY, Sept. 28, 2020 (HealthDay News) -- During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.
PrEP Prescribing Low in the U.S., Even Among HIV Care Providers
TUESDAY, Sept. 22, 2020 (HealthDay News) -- Even among HIV-focused practitioners, preexposure prophylaxis (PrEP) prescribing is not routine, according to a study published online Sept. 3 in PLOS ONE.
Widespread Avoidance of Medical Care Found Due to COVID-19 Concerns
THURSDAY, Sept. 10, 2020 (HealthDay News) -- There was widespread reporting of avoidance of medical care due to COVID-19-related concerns in June 2020, according to research published in the Sept. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Insurer, Insured Costs for HIV PrEP Rising in the United States
WEDNESDAY, Sept. 9, 2020 (HealthDay News) -- From 2014 to 2018, there were increases noted in third-party and out-of-pocket (OOP) payments per 30 tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) tablets for HIV preexposure prophylaxis (PrEP), according to a study published online Sept. 8 in the Annals of Internal Medicine.